Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3H2184
Fri, 23.12.2022
Epigenomics AG
Pareto Securities AS publishes buy recommendation for Epigenomics AG share
Berlin (Germany), December 23, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Pareto Securities AS has published an updated research report upgrading Epigenomics AG's share and issuing a buy recommendation. Pareto's analyst [ … ]
Fri, 23.12.2022
Epigenomics AG
Pareto Securities AS publishes buy recommendation for Epigenomics AG share
Berlin (Germany), December 23, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Pareto Securities AS has published an updated research report upgrading Epigenomics AG's share and issuing a buy recommendation. Pareto's analyst [ … ]
Wed, 21.12.2022
Epigenomics AG
Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022
Berlin, Germany, December 21, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") again raises its earnings guidance for the current fiscal year 2022 due to lower costs, including, among others, lower study cos [ … ]
Wed, 21.12.2022
Epigenomics AG
Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022
Berlin, Germany, December 21, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") again raises its earnings guidance for the current fiscal year 2022 due to lower costs, including, among others, lower study cos [ … ]
Wed, 14.12.2022
Epigenomics AG
Epigenomics Releases Performance Data on Next Generation Test
Epigenomics’ Next Generation test demonstrates 84% sensitivity in pre-clinical testing.
Performance exceeds on-market standard of FIT testing for CRC screening.
Berlin (Germany) and San Diego, CA (U.S.A.), December 14, 2022 - Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG [ … ]
Wed, 14.12.2022
Epigenomics AG
Epigenomics Releases Performance Data on Next Generation Test
Epigenomics’ Next Generation test demonstrates 84% sensitivity in pre-clinical testing.
Performance exceeds on-market standard of FIT testing for CRC screening.
Berlin (Germany) and San Diego, CA (U.S.A.), December 14, 2022 - Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG [ … ]
Wed, 14.12.2022
Epigenomics AG
Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test
Combined technologies have the potential to create a high-performance, cost-effective, blood-based CRC testing solution
Berlin (Germany) and San Diego, CA (U.S.A.), December 14, 2022 - Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG (Frankfurt Prim [ … ]
Wed, 14.12.2022
Epigenomics AG
Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test
Combined technologies have the potential to create a high-performance, cost-effective, blood-based CRC testing solution
Berlin (Germany) and San Diego, CA (U.S.A.), December 14, 2022 - Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG (Frankfurt Prim [ … ]
Wed, 14.12.2022
Epigenomics AG
Epigenomics Releases Performance Data on Next Generation Test
Berlin, December 14, 2022- Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that today it has licensed certain patent and technology rights to biomarkers associated with colorectal cancer detection and [ … ]
Wed, 14.12.2022
Epigenomics AG
Epigenomics Releases Performance Data on Next Generation Test
Berlin, December 14, 2022- Epigenomics Inc, a wholly-owned subsidiary of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that today it has licensed certain patent and technology rights to biomarkers associated with colorectal cancer detection and [ … ]